Concert Pharmaceuticals (CNCE) Stock Analysis

What Concert Pharmaceuticals does

Concert Pharmaceuticals, Inc. functions as a biopharmaceutical firm in the clinical development phase, concentrating on the creation of innovative small-molecule therapeutics designed to address autoimmune conditions. Its primary investigational drug, CTP-543, is currently progressing through late-stage (Phase III) clinical trials for the treatment of alopecia areata, a serious autoimmune dermatological ailment. The company maintains strategic alliances with several partners, including Avanir Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Cipla Technologies, and Processa Pharmaceuticals. Established in 2006, the organization's corporate headquarters are situated in Lexington, Massachusetts.

Key metrics

ETFs linked to CNCE

Broad-market and Healthcare sector ETFs an investor holding Concert Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CNCE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Concert Pharmaceuticals?

Concert Pharmaceuticals trades under the ticker CNCE on NASDAQ.

Which exchange is CNCE listed on?

CNCE is listed on NASDAQ.

What sector does Concert Pharmaceuticals operate in?

Concert Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CNCE in a portfolio?

PortView shows CNCE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.